Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color.
people of color
psychedelic
psychedelic experience
psychological flexibility
racial trauma
Journal
Chronic stress (Thousand Oaks, Calif.)
ISSN: 2470-5470
Titre abrégé: Chronic Stress (Thousand Oaks)
Pays: United States
ID NLM: 101701229
Informations de publication
Date de publication:
Historique:
received:
31
03
2021
accepted:
12
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Previous research showed acute psychedelic effects were associated with decreases in racial trauma (RT) symptoms among black, indigenous, and people of color (BIPOC). Among samples comprised primarily of white participants, positive outcomes of psychedelic experiences have been mediated by increases in psychological flexibility. Therefore, we examined whether changes in psychological flexibility from before to after a psychedelic experience mediated the relationship between acute psychedelic effects and changes in RT symptoms among BIPOC. This cross-sectional online survey study included 313 BIPOC (mean age = 33.1; SD = 11.2; female = 57%). A multiple linear regression analysis was used to examine the association between acute psychedelic effects and decreases in RT symptoms in a nonclinical setting; a path analysis was used to explore whether changes in psychological flexibility mediated this relationship. Acute insight and challenging effects were significantly ( This research suggests psychedelics confer potential benefits in decreasing RT symptoms among BIPOC and psychological flexibility may be an important mediator of these effects. Future research should test this hypothesis in a longitudinal clinical trial among BIPOC.
Sections du résumé
BACKGROUND
BACKGROUND
Previous research showed acute psychedelic effects were associated with decreases in racial trauma (RT) symptoms among black, indigenous, and people of color (BIPOC). Among samples comprised primarily of white participants, positive outcomes of psychedelic experiences have been mediated by increases in psychological flexibility. Therefore, we examined whether changes in psychological flexibility from before to after a psychedelic experience mediated the relationship between acute psychedelic effects and changes in RT symptoms among BIPOC.
METHODS
METHODS
This cross-sectional online survey study included 313 BIPOC (mean age = 33.1; SD = 11.2; female = 57%). A multiple linear regression analysis was used to examine the association between acute psychedelic effects and decreases in RT symptoms in a nonclinical setting; a path analysis was used to explore whether changes in psychological flexibility mediated this relationship.
RESULTS
RESULTS
Acute insight and challenging effects were significantly (
CONCLUSION
CONCLUSIONS
This research suggests psychedelics confer potential benefits in decreasing RT symptoms among BIPOC and psychological flexibility may be an important mediator of these effects. Future research should test this hypothesis in a longitudinal clinical trial among BIPOC.
Identifiants
pubmed: 34377878
doi: 10.1177/24705470211035607
pii: 10.1177_24705470211035607
pmc: PMC8342866
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24705470211035607Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: Drs Williams and Davis are board members of Source Research Foundation. This organization was not involved in the design/execution of this study or the interpretation or communication of findings.
Références
J Psychopharmacol. 2021 Apr;35(4):437-446
pubmed: 33427007
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
BMC Psychiatry. 2018 Jul 31;18(1):245
pubmed: 30064392
Psychol Trauma. 2019 May;11(4):383-390
pubmed: 30148370
CNS Spectr. 2009 Jan;14(1 Suppl 1):32-43
pubmed: 19169192
J Psychopharmacol. 2021 Apr;35(4):362-374
pubmed: 33853422
J Psychopharmacol. 2018 Jul;32(7):779-792
pubmed: 29708042
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
Psychiatry. 2008 Summer;71(2):134-68
pubmed: 18573035
Behav Ther. 2018 May;49(3):435-449
pubmed: 29704971
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
J Am Acad Psychiatry Law. 2002;30(3):336-9
pubmed: 12380410
Behav Ther. 2011 Dec;42(4):676-88
pubmed: 22035996
Psychopharmacology (Berl). 2011 Dec;218(4):649-65
pubmed: 21674151
Eur J Psychotraumatol. 2019 Aug 16;10(1):1648173
pubmed: 31489137
J Anxiety Disord. 2009 Jun;23(5):578-90
pubmed: 19231131
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
J Adolesc Health. 2018 Sep;63(3):348-356
pubmed: 30237000
J Contextual Behav Sci. 2020 Jan;15:39-45
pubmed: 32864325
J Psychopharmacol. 2019 Sep;33(9):1088-1101
pubmed: 31084460
J Consult Clin Psychol. 1991 Oct;59(5):715-23
pubmed: 1955605
J Trauma Stress. 2020 Aug;33(4):420-431
pubmed: 32521089
Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213
pubmed: 27354908
Psychiatry. 2008 Fall;71(3):234-45
pubmed: 18834274
J Psychopharmacol. 2015 Nov;29(11):1182-90
pubmed: 26442957
J Affect Disord. 2016 Jan 1;189:10-6
pubmed: 26402342
Cogn Behav Ther. 2019 Jan;48(1):1-14
pubmed: 30332919
Drugs (Abingdon Engl). 2021;28(3):215-226
pubmed: 34349358
J Behav Med. 2006 Feb;29(1):79-94
pubmed: 16470345
Am J Public Health. 2003 May;93(5):792-7
pubmed: 12721146
Am J Drug Alcohol Abuse. 2019;45(2):161-169
pubmed: 30822141
J Psychopharmacol. 2017 Jul;31(7):841-850
pubmed: 28095732
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
Curr Top Behav Neurosci. 2018;36:221-256
pubmed: 28025814
J Ethnopharmacol. 2007 Jul 25;112(3):507-13
pubmed: 17532158
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Int Rev Psychiatry. 2018 Aug;30(4):343-349
pubmed: 30251904
Clin Psychol Rev. 2010 Nov;30(7):865-78
pubmed: 21151705
Neurotherapeutics. 2017 Jul;14(3):734-740
pubmed: 28585222
Psychiatr Clin North Am. 2017 Dec;40(4):751-770
pubmed: 29080598
Front Hum Neurosci. 2014 Feb 03;8:20
pubmed: 24550805
Psychol Addict Behav. 2012 Sep;26(3):550-60
pubmed: 22545585
Dev Psychol. 2014 Jul;50(7):1910-8
pubmed: 24730378
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
J Psychopharmacol. 2016 Dec;30(12):1279-1295
pubmed: 27856683
Sci Rep. 2017 Oct 13;7(1):13187
pubmed: 29030624
J Psychopharmacol. 2011 Nov;25(11):1453-61
pubmed: 21956378
Psychopharmacology (Berl). 2016 Sep;233(18):3395-403
pubmed: 27435062
Psychopharmacology (Berl). 2018 Oct;235(10):2979-2989
pubmed: 30105399
Am J Public Health. 2010 May;100(5):933-9
pubmed: 19846689
J Health Care Poor Underserved. 2013 Feb;24(1):78-88
pubmed: 23377719
Int Rev Psychiatry. 2018 Aug;30(4):331-342
pubmed: 30260256
Suicide Life Threat Behav. 2018 Dec;48(6):627-641
pubmed: 28891193
Behav Sci (Basel). 2014 May 14;4(2):102-124
pubmed: 25379272